Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Research & Development (2016 - 2025)

Historic Research & Development for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $51.2 million.

  • ImmunityBio's Research & Development rose 156.41% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.9 million, marking a year-over-year decrease of 800.76%. This contributed to the annual value of $190.1 million for FY2024, which is 1817.05% down from last year.
  • ImmunityBio's Research & Development amounted to $51.2 million in Q3 2025, which was up 156.41% from $55.2 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Research & Development registered a high of $79.3 million during Q1 2023, and its lowest value of $35.2 million during Q4 2024.
  • Its 5-year average for Research & Development is $53.8 million, with a median of $51.8 million in 2021.
  • In the last 5 years, ImmunityBio's Research & Development soared by 6300.56% in 2021 and then plummeted by 3269.2% in 2024.
  • Over the past 5 years, ImmunityBio's Research & Development (Quarter) stood at $51.8 million in 2021, then grew by 12.22% to $58.1 million in 2022, then fell by 11.27% to $51.5 million in 2023, then tumbled by 31.65% to $35.2 million in 2024, then soared by 45.46% to $51.2 million in 2025.
  • Its Research & Development was $51.2 million in Q3 2025, compared to $55.2 million in Q2 2025 and $48.2 million in Q1 2025.